Britain’s Oxford University said on Wednesday it would study whether the world’s best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.
The AVID-CC trial will test the anti-tumour necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enrol up to 750 patients from community care settings throughout the UK.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.